Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immunologic Desensitization Clear all
Completed Phase 2 Interventional Results available

The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery

NCT02103270
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut Protein 4,000mg, Oat Flour, Peanut Protein 300 mg
Drug
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 6, 2026, 2:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Carfilzomib and Belatacept for Desensitization

NCT05017545
View directory record Official record
Conditions
Highly Sensitized Prospective Kidney Transplant Recipients
Interventions
carfilzomib, belatacept, Bone marrow aspiration
Biological · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Mechanisms of Desensitization During Peanut Oral Immunotherapy

NCT01814241
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Open label peanut OIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 6, 2026, 2:22 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy

NCT02676765
View directory record Official record
Conditions
Immunologic Desensitization
Interventions
allergen extract tablet, Placebo tablet
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 1 Interventional

Desensitization of Renal Transplant Candidates

NCT00298883
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Transplantation
Interventions
Myfortic
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

NCT03292484
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
1 Year to 55 Years
Enrollment
911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
65
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 6, 2026, 2:22 AM EDT
Terminated Phase 2 Interventional Results available

Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant

NCT01025193
View directory record Official record
Conditions
Desensitization
Interventions
Belimumab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 6, 2026, 2:22 AM EDT
Withdrawn Not applicable Interventional

EoE Food Desensitization

NCT02881372
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Oral food desensitization
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial

NCT01781637
View directory record Official record
Conditions
Peanut Allergy, Food Allergy
Interventions
Omalizumab, placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years to 25 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 6, 2026, 2:22 AM EDT
Withdrawn Not applicable Interventional

Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant

NCT00167791
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
rituximab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

NCT02198664
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 - Peanut protein capsule
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 6, 2026, 2:22 AM EDT
Terminated Phase 2 Interventional Results available

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

NCT04056299
View directory record Official record
Conditions
Hen Egg Allergy
Interventions
AR201 powder, Placebo powder
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 6, 2026, 2:22 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Identification of Donor Specific B Cells and Antibody Mediated Rejection

NCT02133248
View directory record Official record
Conditions
Sensitized Kidney Transplant Recipients
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

NCT01178216
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Rituxan
Biological
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Xolair Enhances Oral Desensitization in Peanut Allergic Patients

NCT01290913
View directory record Official record
Conditions
Peanut Allergy
Interventions
Omalizumab
Drug
Lead sponsor
Lynda Schneider
Other
Eligibility
7 Years to 25 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation

NCT02426684
View directory record Official record
Conditions
Renal Disease
Interventions
IdeS® (Imlifidase)
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

NCT02013037
View directory record Official record
Conditions
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy, Heart Graft Dysfunction
Interventions
Eculizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 6, 2026, 2:22 AM EDT
Enrolling by invitation Phase 2 Interventional

Daratumumab in HLA Desensitization Prior to Transplantation

NCT05300451
View directory record Official record
Conditions
Cardiac Transplant
Interventions
Daratumumab and hyaluronidase-fihj
Biological
Lead sponsor
Barry A. Boilson
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)

NCT01597375
View directory record Official record
Conditions
Asthma, Aspirin-Induced, Aspirin Exacerbated Asthma
Interventions
Placebo Oral Tablet, Prasugrel Oral Tablet
Drug
Lead sponsor
Elliot Israel, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

NCT02635776
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
49
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy

NCT01846208
View directory record Official record
Conditions
Food Allergy
Interventions
Egg Oral Immunotherapy, Baked Egg
Drug
Lead sponsor
Hugh A Sampson, MD
Other
Eligibility
3 Years to 16 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

NCT04856865
View directory record Official record
Conditions
Food Allergy
Interventions
Low dose ADP101, High dose ADP101, Pooled Placebo
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Peanut Oral Immunotherapy in Children

NCT01867671
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut Oral Immunotherapy - Liquid Extract, Placebo for Peanut Oral Immunotherapy - Liquid Extract form, Peanut Oral Immunotherapy - Peanut Flour, Placebo for Peanut Oral Immunotherapy - Peanut Flour
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 48 Months
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Stanford, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Sep 6, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

PALISADE Follow-on Study (ARC004)

NCT02993107
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
47
States / cities
Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 6, 2026, 2:22 AM EDT